| Filed On | Filing |
|---|---|
| 16 Jul 2025 |
8-K/A: Financial Statements and Exhibits
Buyer, Biofrontera AG, Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH each a “Party” and together the “Parties” to Acquire US Assets of Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH |
| 03 Apr 2024 |
8-K/A: Other Events
On April 3, 2024, the Company changed the record date for the determination of stockholders entitled to notice of and to vote at the 2024 Annual Meeting from April 22, 2024, as reported in the Original Form 8-K, to April 15, 2024. |
| 09 Jan 2024 |
8-K/A: Termination of a Material Definitive Agreement
Effective as of January 4, 2024, the Company terminated the MidCap Loan Agreement. In connection with the termination, the Company paid a $150,000 prepayment fee to MidCap. As reported in the Original Form 8-K, the Company terminated the... |
| 24 May 2022 | 8-K/A: Departure/Election of Directors or Officers; Compensation |
Loading...
